D2R announces new round of funding, investing $1.5 million to advance research in Ï㽶ÊÓƵ therapeutics and to support McGill Centres and Institutes
Montreal – December 19, 2024 – The D2R (DNA to Ï㽶ÊÓƵ) Initiative is proud to announce the recipients of its latest round of funding, awarding a total of $1.5 million to four principal investigators and five Ï㽶ÊÓƵ Centres and Institutes. These awards are designed at advancing research in Ï㽶ÊÓƵ therapeutics by facilitating industry collaboration and supporting the next generation of scientific leaders as well as research Centres and Institutes.
Research | A new trial hopes to use mÏ㽶ÊÓƵ to halt the devastating progression of Creutzfeldt-Jakob Disease
Prion diseases came to public attention during the 1980s and ’90s, when Mad Cow Disease was in the news. While transmission to humans from infected beef has largely been eliminated, other forms of these devastating diseases are unfortunately still around, like Creutzfeld-Jacob Disease (CJD). In fact, according to the US Centers for Disease Control, cases of CJD have been on the rise in the last two decades.
Event | Seminar, The power of first impressions: Using viral imprinting for broadly reactive vaccine development | Dec 11, 2024
The Emerging Topics in Health (EToH) seminar series is cohosted by the Departments of Microbiology and Immunology, Physiology and Human Genetics, the Goodman Cancer Institute (GCI), the Ï㽶ÊÓƵ Research Centre on Complex Traits (MRCCT), and M[i]4. The organizers invite guest speakers to talk about their current research. This seminar series is part of the Current Topics & Seminars course and is open for attendance by MIMM students and all interested individuals.
CQDM partners with D2R to enhance collaborations among researchers and industry in Ï㽶ÊÓƵ research
Montréal, November 28th – CQDM is proud to announce a strategic partnership with the D2R (DNA to Ï㽶ÊÓƵ) Initiative at Ï㽶ÊÓƵ, aimed at funding translational research projects carried out through collaborations between researchers and industry. This alliance seeks to support and accelerate the development and commercialization of innovative Ï㽶ÊÓƵ-based therapies.
Event | Workshop in Precision Health and Medicine | January 9, 2025
First Hybrid Workshop on Precision Health and MedicineSynergizing our strengths in new technologies in omics, digital sciences, and translational medicine to advance patient care.
Event | MI4 6th Annual Scientific Symposium | December 4, 2024
Join MI4 for the 6th Annual Scientific Symposium on Wednesday, December 4, 2024, from 11:30 PM to 5:30 PM at the McGill Faculty Club. This year’s theme, "Microbiome: Decoding the Invisible World," promises an engaging lineup, including a keynote by Prof. Yasmine Belkaid, President of Institut Pasteur. Don’t miss this chance to hear groundbreaking insights from leading experts in the MI4 community.
Event | Practical examples of research in indigenous context | November 20, 2024
D2R partner, Tahatikonhsontóntie' Quebec Network Environment for Indigenous Health Research, is organizing a webinar "Practical examples of research in Indigenous context" on November 20 from 12-1:30pm.Â
Guest speakers include:Â
Event | Antisense oligonucleotide therapy in an individual with KIF1A-associated neurological disorder | November 14, 2024
Dear Colleagues,
Please see the next Medical Genetics Grand Rounds scheduled talk below:
Philippe Gros appointed Chief Scientific Officer of D2R
Philippe Gros appointed Chief Scientific Officer of D2RPhilippe Gros has been appointed Chief Scientific Officer (CSO) of McGill’s DNA to Ï㽶ÊÓƵ (D2R) Initiative, effective September 30, 2024. Prior to this role, he served as Deputy Vice-President (Research and Innovation) at McGill. This appointment follows a thorough international search, with the selection committee enthusiastic about their recommendation.
D2R welcomes Ï㽶ÊÓƵ and genomic researchers to Université de Sherbrooke
D2R welcomes Ï㽶ÊÓƵ and genomic researchers to Université de SherbrookeMontreal – October 31, 2024 – Ï㽶ÊÓƵ’s DNA to Ï㽶ÊÓƵ (D2R) research initiative is proud to announce the appointment of three new researchers at Université de Sherbrooke, marking the inaugural recipients of the D2R’s New Faculty Start-Up funding program. Université de Sherbrooke is a partner institution in the D2R initiative, working collaboratively to advance genomic and Ï㽶ÊÓƵ research.
Event | Practical research experience in a First Nations environment in the field of health and social services evaluation | Dec 20, 2024
Practical research experience in First Nations communities in the field of health and social services evaluationDecember 20, 2024 | 12 h à 13 h Speaker: Cecilia Valdebenito, anthropologist
This webinar has two objectives:
News | 2024 Nobel Prize awarded to Victor Ambros and Gary Ruvkun for the discovery of microÏ㽶ÊÓƵ and its role in post-transcriptional gene regulation
The 2024 Nobel Prize in Physiology or Medicine has been awarded to Victor Ambros and Gary Ruvkun for the discovery of microÏ㽶ÊÓƵ and its role in post-transcriptional gene regulation.This year’s Nobel Prize focuses on the discovery of a vital regulatory mechanism used in cells to control gene activity. Genetic information flows from DNA to messenger Ï㽶ÊÓƵ (mÏ㽶ÊÓƵ), via a process called transcription, and then on to the cellular machinery for protein production.
Event | Controlling Ï㽶ÊÓƵ Sequence for Diagnostics and Therapeutic Delivery | January 5-10, 2025
Ï㽶ÊÓƵ Nanotechnology - Gordon Research Conference (GRC) Controlling Ï㽶ÊÓƵ Sequence for Diagnostics and Therapeutic DeliveryJanuary 5 - 10, 2025
Ventura, California, United States
Congratulations to Dr. Raquel Cuella Martin on receiving Gairdner Foundation Early Career Investigator Award
Congratulations to Dr. Raquel Cuella Martin on receiving the prestigious Gairdner Foundation Early Career Investigator Award. As an Assistant Professor of Human Genetics at Ï㽶ÊÓƵ, Dr. Cuella Martin is pushing the boundaries of science with her lab, which uses precision genome editing to tackle complex biological problems.
News | Génome Québec invests up to $500,000 to boost Ï㽶ÊÓƵ therapeutics innovation in Quebec
Génome Québec invests up to $500,000 to boost Ï㽶ÊÓƵ therapeutics innovation in QuebecGénome Québec, a private, non-profit organization dedicated to advancing genomics research and innovation in Quebec, is investing up to $500,000 in Ï㽶ÊÓƵ’s D2R Initiative. This investment will advance the commercialization of innovative genomic technologies in Quebec through D2R’s Commercialization Priming funding program.